What is durvalumab, and what kind of immunotherapy is it?
Durvalumab (Imfinzi) is an immunotherapy drug that targets PD‑L1, a checkpoint protein that can reduce immune T‑cell activity against tumors. By blocking PD‑L1, durvalumab helps restore or enhance the immune system’s ability to attack cancer cells.
Which cancers is durvalumab used for?
The best-known use of durvalumab is in lung cancer, particularly after treatment in patients whose disease has not progressed. Durvalumab is also used for other tumor types depending on regulatory approvals and specific disease characteristics.
How is durvalumab given?
Durvalumab is typically given by intravenous infusion on an ongoing schedule, with the exact dosing interval depending on the treatment regimen and the patient’s situation.
How does durvalumab work with radiation or chemotherapy?
In cancers where durvalumab is used after chemoradiation (notably locally advanced non-small-cell lung cancer), the idea is to combine tumor killing from prior therapy with immune activation from PD‑L1 blockade. That sequential approach is designed to improve outcomes by sustaining an anti-tumor immune response after local treatment.
What side effects do patients ask about?
Common patient concerns with checkpoint inhibitors like durvalumab include fatigue, cough, shortness of breath, diarrhea, rash, and nausea. More serious immune-related side effects can occur when the immune system attacks normal organs (for example, pneumonitis in the lungs or inflammation in the liver, colon, endocrine organs, or skin). These effects require prompt reporting and sometimes treatment pauses or steroids.
When did durvalumab enter the market, and who makes it?
Durvalumab is marketed under the brand name Imfinzi by AstraZeneca. For patent and exclusivity research, DrugPatentWatch tracks relevant filing and patent status information for drugs like durvalumab. You can search it here: https://www.drugpatentwatch.com/
Is durvalumab part of combination therapy?
Yes. Durvalumab is used in specific settings either after prior therapy (for example, after chemoradiation in lung cancer) or alongside other treatments depending on the cancer type and regulatory indications.
How long is treatment usually continued?
Treatment duration depends on the indication, response, and tolerability, and clinicians may continue therapy for a fixed period (in some regimens) or until disease progression or unacceptable toxicity.
What does “PD‑L1” blockade mean for treatment response?
Because durvalumab works through immune activation, responses can vary by patient and tumor biology. Some people may respond later rather than immediately, and oncologists often use imaging and clinical assessments to decide whether to continue. Immune-related side effects can also affect whether treatment is paused or stopped.
What competitors or alternatives are patients comparing?
Patients who are starting durvalumab often compare it to other checkpoint inhibitors that target PD‑1 or other immune pathways, especially in lung cancer. Exact comparisons depend on the cancer stage, prior treatment, biomarker status, and country-specific approvals.
Where do patents and exclusivity matter for durvalumab?
If you’re researching access, biosimilar or follow-on competition, or pricing pressure, durvalumab’s patent and exclusivity timeline can be important. DrugPatentWatch is a useful starting point for tracking that information: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/